Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?

1Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Objectives: Monoclonal gammopathy of undetermined significance (MGUS) is a premalignancy preceding multiple myeloma (MM) or related disorders. Neurological symptoms caused by the monoclonal immunoglobulins or free light-chains are often associated with a high morbidity. We analyzed the prevalence of neuropathy, clinical features and the long-term outcome in 223 patients (pts.) with MGUS. Patients and Methods: Between 1/2005 and 3/2015, 223 adult pts. with MGUS were identified in our database. Results: In36/223 pts. (16%) a neuropathy was diagnosed (MGUS associated neuropathy, MGUS-N). 20 pts. (55%) had a distal symmetric axonal neuropathy, 10 pts. (28%) had a chronic inflammatory demyelinating polyneuropathy and 6 pts (17%) a distal acquired demyelinating symmetric polyneuropathy. In MGUS-NN (without neuropathy) and in MGUS-N, progression to smoldering MM, MM or Waldenstrom's macroglobulinemia (WM) occurred in 17% of the pts. The Immunoglobulin subtype was predominantly IgG in MGUS-NN and IgM in MGUS-N and ≥ 5.5% plasma cells in the bone-marrow predicted progression to MM and AL-amyloidosis in MGUS-NN and to WM in MGUS-N (p < 0.05). Conclusion: Due to the substantial prevalence of neuropathies, MGUS pts. should be monitored carefully and referred to a specialized center if neurological symptoms occur.

Cite

CITATION STYLE

APA

Steiner, N., Schwärzler, A., Göbel, G., Löscher, W., Wanschitz, J., & Gunsilius, E. (2017). Are neurological complications of monoclonal gammopathy of undetermined significance underestimated? Oncotarget, 8(3), 5081–5091. https://doi.org/10.18632/oncotarget.13861

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free